Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07640984 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
A Phase 1 study, sponsored by JCR Pharmaceuticals Co..
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07640984 is a Phase 1 study that has not yet begun recruiting, run by JCR Pharmaceuticals Co.. The registered enrollment target is 12 participants.
The verdict
NCT07640984, a Phase 1 study, has not yet begun recruiting, sponsored by JCR Pharmaceuticals Co..
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its pharmacodynamic effects, and explore its potential to demonstrate early clinical effects on disease-relevant outcomes.
Interventions
- DRUG JR-446
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-06-18 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07640984
The ClinicalTrials.gov registry entry for NCT07640984 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JCR Pharmaceuticals Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JR-446 is the first listed.
NCT07640984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07640984 about?
NCT07640984 is a clinical study titled "A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)". This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its pharmacodynamic effects, and explore its potential to demonstrate early ...
What is the current status of trial NCT07640984?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-06-18. Estimated completion is 2028-09-30.
What interventions are being tested in trial NCT07640984?
The interventions under investigation include: JR-446 (DRUG).
Who is sponsoring clinical trial NCT07640984?
This trial is sponsored by JCR Pharmaceuticals Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.